TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00321620
Status
COMPLETED
Phase
PHASE3
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00321620
Indication
Bone Metastases
Modality
monoclonal antibody
Target
zoledronic acid, denosumab
Intervention
zoledronic acid, denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.